(Q38016073)

27 August 2017

title

Bone turnover markers: use in osteoporosis (English)

1 reference

27 August 2017

0 references

2

Richard Eastell

1 reference

27 August 2017

Kim Naylor

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

5 June 2012

1 reference

Nature Reviews Rheumatology

27 August 2017

published in

1 reference

27 August 2017

volume

8

1 reference

27 August 2017

issue

7

1 reference

27 August 2017

page(s)

379-389

1 reference

The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Bone turnover markers in the management of postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

The osteoblast: an insulin target cell controlling glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Preanalytical variability of biochemical markers of bone turnover.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Measurement of osteocalcin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Effect of feeding on bone turnover markers and its impact on biological variability of measurements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Role of gastrointestinal hormones in postprandial reduction of bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Urinary excretion of cross-linked N-telopeptides of type 1 collagen to assess bone resorption in infants from birth to 1 year of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Changes in bone mass and bone turnover following tibial shaft fracture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Establishing a reference range for bone turnover markers in young, healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Determinants of bone turnover markers in healthy premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Osteoporosis prevention, diagnosis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Common biochemical markers of bone turnover predict future bone loss: a 5-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

New targets for intervention in the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Benefits and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

A cross-sectional study of bone turnover markers in healthy premenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Alendronate for the Treatment of Osteoporosis in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Efficacy and safety of monthly ibandronate in men with low bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

PINP as an aid for monitoring patients treated with teriparatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Effect of stopping risedronate after long-term treatment on bone turnover.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Changes in bone density and turnover after alendronate or estrogen withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Relation of age, gender, and bone mass to circulating sclerostin levels in women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Monitoring alendronate therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Using biochemical markers of bone turnover in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Analysis of pyridinoline, a cross-linking compound of collagen fibers, in human urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Urinary N-telopeptides of type I collagen in healthy children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

The effect of pregnancy on bone density and bone turnover

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Comparison of the acute alterations in serum bone turnover markers and bone mineral density among women with surgical menopause

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Estimating reference intervals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

A placebo-controlled study of three osteocalcin assays for assessment of prednisolone-induced suppression of bone turnover

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Clinical relevance of FGF-23 in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Biochemical markers as predictors of rates of bone loss after menopause

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Bone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Biochemical markers of bone metabolism and prediction of fracture in elderly women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Biochemical indices of bone turnover and the assessment of fracture probability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

The potential value of monitoring bone turnover markers among women on alendronate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Effect of Monitoring Bone Turnover Markers on Persistence with Risedronate Treatment of Postmenopausal Osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Transmission of human herpesvirus 8 by blood transfusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Rapid and robust response of biochemical markers of bone formation to teriparatide therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Determinants of serum sclerostin in healthy pre- and postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

Circulating Fibroblast Growth Factor-23 Increases Following Intermittent Parathyroid Hormone (1–34) in Postmenopausal Osteoporosis: Association with Biomarker of Bone Formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

The role of Dkk1 in bone mass regulation: correlating serum Dkk1 expression with bone mineral density

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.86

The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment.

31 March 2020

1 reference

12 December 2020

Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption.

1 reference

12 December 2020

Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels

1 reference

12 December 2020

Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen

1 reference

12 December 2020

Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study

1 reference

12 December 2020

Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation

1 reference

12 December 2020

Intraindividual variability in bone markers in the urine

1 reference

12 December 2020

Interlaboratory variation of biochemical markers of bone turnover.

1 reference

12 December 2020

The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation

1 reference

12 December 2020

Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis

1 reference

12 December 2020

Molecular basis and clinical application of biological markers of bone turnover

1 reference

12 December 2020

Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease.

1 reference

12 December 2020

Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline.

1 reference

12 December 2020

Biochemical markers of bone turnover: part I: biochemistry and variability

1 reference

12 December 2020

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

1 reference

12 December 2020

Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption

1 reference

12 December 2020

Immunoassay for quantifying type I collagen degradation products in urine evaluated

1 reference

12 December 2020

Immunoassay for intact amino-terminal propeptide of human type I procollagen.

1 reference

12 December 2020

Characterization of aged osteocalcin fragments derived from bone resorption.

1 reference

12 December 2020

Diurnal rhythm of CrossLaps in human serum

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2012.86

1 reference

Dimensions Publication ID

27 August 2017

1015580657

0 references

1 reference